TYRP1 and melanoma: In a recent study, researchers used RORγ agonist to prime TRP-1 transgenic Th17 cells and Pmel-1 TCR transgenic CD8+ T cells ex vivo and found these cells could effectively regress melanoma compared with those untreated Th17 cells.